• Stable Annual Subscription: We offer an annual subscription of $5,000 USD per hospital that implements our software, EpyDiagnosis. This model provides us with a steady and predictable revenue stream, regardless of the number of diagnoses made.
• Competitive Diagnostic Cost: We charge $20 USD for each diagnosis made with EpyDiagnosis. However, we understand the importance of being accessible, especially in Latin American economies. Therefore, over the next four years, we will reduce the price by 5% annually, reaching a final cost of just $16.29 USD per diagnosis. This price is more competitive than those of our competitors, positioning us as an attractive and affordable option in the market.
• Exponential Growth: Our revenue projection is exponentially enhanced by the expected growth in the number of hospitals and diagnoses:
  • Year 1: 2 hospitals // 2,591 annual diagnoses
  • Year 2: 6 hospitals // 7,248 annual diagnoses
  • Year 3: 13 hospitals // 15,948 annual diagnoses
  • Year 4: 21 hospitals // 24,804 annual diagnoses
  • Year 5: 27 hospitals // 36,912 annual diagnoses

• R&D Expense: Set at a strategic 10% of the previous year’s earnings to fuel continuous innovation. Initially pegged at $8,000 USD, reflecting 26.67% of our seed capital allocation.
• Google Cloud: Begins at a monthly $1,267.70, inflating by 30% on year 2 since in both of the years the . A notable 44% uptick in Year 3 corresponds with a surge in hospital partnerships.
• Colab Pro Subscription: Locked at $700 annually, a cornerstone for our development team’s collaborative efforts.
• Testing and Validation: Astutely managed in-house, this cost remains $0 in the initial phase, leveraging our team’s expertise to maintain quality.
• Health Registration of Medical Devices: EpyDiagnosis classifies as a Nationally Manufactured Product Considered Low Risk (COFEPRIS-04-001-I) and the one-time $922.92 payment covers the tool for 5 years (the process takes 30 days).
• Personnel Costs: Shrewdly deferred for Year 1 through voluntary contributions from our founding team, with competitive salaries integrated from Year 2 to attract top talent and sustain our expanding service requirements.
  • IA Software engineer
  • Sales representative
  • Finance and accounting administration
  • General office administration
  • Software hospital trainer
• Data Acquisition (TC Scans): Skillfully negotiated to $0, thanks to a symbiotic agreement with IMSS, highlighting our strategic alliances.
• Mexican Patent (20 years): An investment in intellectual property, the $5,278 MXN patent cost is spread over two decades as established by the Mexican law system.
• Contingency Expense: Prudently reserved at 10% of annual costs, our emergency fund is a testament to our risk-aware financial planning.

With a strategic focus, our Break Even Point reflects the precision of our operations. In Year 1, it takes 1,399 diagnostic procedures, at a revenue of $33,848.56, to balance costs with earnings. By Year 5, this point stretches to 6702 procedures, generating $339,752.66, evidencing the scalability of our services. Significantly, these figures are grounded solely in diagnostic revenue, a conservative stance that highlights the potency and potential of our core business model.

• Mexico’s main healthcare provider is the IMSS, with over 50% of the population having access to its numerous hospitals and high-level facilities.
• The IMSS has 36 Third-Level Medical Units, consisting of 25 High Specialty Medical Units (UMAE) and 11 Complementary Medical Units (IMSS, 2021). As of today we were able to completely confirm that at least 16 of these units perform CT scans aimed at diagnosing lung cancer.
• According to our partner Oncologist, Monterrey’s UMAE No 25 detects an average of 127 cases of lung cancer each month.
• Based on population data from INEGI, beneficiary information from IMSS, and insights from our partner at High Specialty Medical Unit (UMAE) No 25, and the oncologists of the main UMAEs, we estimated the minimum number of lung cancer screenings that can be conducted in the Medical Units we identified as capable of performing CT scans.